CIK 0001980845 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
enGene Therapeutics Inc.
Sign in to watch- Ticker
- ENGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Oct 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- (514) 332-4888
- Business address
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
- Former names
- enGene Holdings Inc.
Securities
- ENGN Common Stock Nasdaq
- ENGNW Warrants Nasdaq
- 424B3 Offering Prospectus
- 8-K Event Material agreement · Unregistered share sale · Regulation FD disclosure
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 424B3 Offering Prospectus
- 8-K Event Executive or director change · Regulation FD disclosure · Other events
- SC 13D/A Stake Beneficial Ownership Report
- 4 Open-market buy 10% owner bought 470,633 shares at an average $6.40 ($3,012,674)
- 4 Open-market buy Chief Executive Officer bought 10,000 shares at $5.70 ($57,000)
- 424B3 Offering Prospectus
- 8-K Event Regulation FD disclosure · Other events
- 424B3 Offering Prospectus
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Regulation FD disclosure
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
Page 8 of 14 · 268 filings